Wolf Group Capital Advisors Cuts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Wolf Group Capital Advisors trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,712 shares of the biopharmaceutical company’s stock after selling 5,086 shares during the quarter. Gilead Sciences accounts for approximately 1.4% of Wolf Group Capital Advisors’ investment portfolio, making the stock its 17th largest position. Wolf Group Capital Advisors’ holdings in Gilead Sciences were worth $4,226,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of GILD. Brighton Jones LLC boosted its stake in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the period. Everhart Financial Group Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter worth $239,000. Principal Securities Inc. lifted its position in shares of Gilead Sciences by 45.0% during the fourth quarter. Principal Securities Inc. now owns 14,404 shares of the biopharmaceutical company’s stock worth $1,330,000 after purchasing an additional 4,468 shares during the last quarter. Allworth Financial LP lifted its position in shares of Gilead Sciences by 24.8% during the fourth quarter. Allworth Financial LP now owns 35,953 shares of the biopharmaceutical company’s stock worth $3,345,000 after purchasing an additional 7,143 shares during the last quarter. Finally, J.W. Cole Advisors Inc. lifted its position in shares of Gilead Sciences by 1.0% during the fourth quarter. J.W. Cole Advisors Inc. now owns 13,597 shares of the biopharmaceutical company’s stock worth $1,256,000 after purchasing an additional 135 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on GILD shares. Cantor Fitzgerald started coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 target price for the company. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Bank of America lifted their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the sale, the chief financial officer now owns 165,674 shares in the company, valued at $16,537,578.68. This represents a 1.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares in the company, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,500 shares of company stock worth $5,236,245. Insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

GILD opened at $108.00 on Wednesday. The business’s 50-day moving average is $105.88 and its two-hundred day moving average is $102.49. Gilead Sciences, Inc. has a 1 year low of $62.69 and a 1 year high of $119.96. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The firm has a market capitalization of $134.34 billion, a PE ratio of 22.74, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the previous year, the firm earned ($1.32) earnings per share. The company’s revenue was down .3% on a year-over-year basis. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.93%. Gilead Sciences’s payout ratio is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.